Brain White Matter Microstructure are not associated with Blood Markers of the GSH Redox cycle in Schizophrenia

Tommaso Pavan[1], Pascal Steullet[2], Yasser Alemán-Gómez[1], Raoul Jenni[2], Zoé Schilliger[2,6], Martine Cleusix[2], Luis Alameda[3,4,5], Kim Q. Do[2], Philippe Conus[3], Patric Hagmann[1], Daniella Dwir[2], Paul Klauser[2,6], and Ileana Jelescu[1]

1. Department of Radiology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland

2. Center for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital and the University of Lausanne, Lausanne, Switzerland

3. Service of General Psychiatry, Treatment and Early Intervention in Psychosis Program. Lausanne University Hospital (CHUV), Lausanne, Switzerland

4. Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience. King's College of London, London, UK.

5. Centro Investigacion Biomedica en Red de Salud Mental (CIBERSAM); Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del Rocio, Departamento de Psiquiatria, Universidad de Sevilla, Sevilla, Spain.

6. Service of Child and Adolescent Psychiatry, Department of Psychiatry, Lausanne University Hospital and the University of Lausanne, Lausanne, Switzerland

Corresponding author: Tommaso Pavan; address: *Centre de Recherche en Radiologie*, PET3, CHUV, Rue du Bugnon 46, 1011, Lausanne, Switzerland ; telephone:+41213146020; fax:+41213146020; email: tommaso.pavan@chuv.ch

Abstract

In groups of patients suffering from schizophrenia (SZ), redox dysregulation was reported in both peripheral fluids and brain. It has been hypothesized that such dysregulation, including alterations of the glutathione (GSH) cycle could participate in the brain white matter (WM) abnormalities in SZ due to the oligodendrocytes' susceptibility to oxidative stress (OxS).

In this study we aim to assess the differences between 82 schizophrenia patients (PT) and 86 healthy controls (HC) in GSH-redox peripheral blood markers: GSH peroxidase (GPx), reductase (GR) enzymatic activities and their ratio (GPx/GR-ratio), evaluating the hypotheses that alterations in the homeostasis of the systemic GSH cycle may be associated with pathological mechanisms in the brain WM in PT. To do so, we employ the advanced diffusion MRI methods: Diffusion Kurtosis Imaging (DKI) and White Matter Tract Integrity-Watson (WMTI-W), which provide excellent sensitivity to demyelination and neuroinflammation.

We show that GPx levels are higher (p=0.00071) in female participants (HC and PT combined) and decrease with aging (p=0.026). We find differences between PT and HC in the association of GR and mean kurtosis (MK, p<0.0001). Namely, lower MK was associated with higher blood GR activity in HC, but not in PT, suggesting that high GR activity (a hallmark of reductive stress) in HC was linked to changes in myelin integrity. However, GSH-redox peripheral blood markers did not explain the WM anomalies detected in PT, or the design of the present study could not detect subtle phenomenon, if present.

Introduction

Psychosis and schizophrenia (SZ) present significant challenges for patients, their families, and society[1]. Only partially understood, its etiology is attributed to a multifaceted interplay of genetic, environmental and developmental factors that affect a variety of biological processes[2-7] among which the redox balance[8]. In patients suffering from psychosis and schizophrenia, a redox dysregulation is reported in peripheral fluids (i.e., diminished antioxidant capacity, oxidative damage of lipids, DNA and RNA[9-11]) and brain (i.e., lower glutathione (GSH), lower NAD+/NADH ratio[12,13]). The causes of such redox dysregulation and the resulting oxidative stress (OxS) are multifactorial, including compromised energy metabolism, endocrine dysregulation, chronic subclinical inflammation and weakened antioxidant capacities. Anomalies in the GSH redox system, a key antioxidant system for cell protection and detoxification, have been widely observed in SZ[9]. While polymorphisms in genes of the GSH system have been associated with SZ[14-19], meta-analyses also show lower mean levels of GSH in blood[9], and brain[13,20-22] in patients vs. controls.

The redox regulation and antioxidant function of GSH acts largely via the GSH redox cycle that involves the GSH peroxidase (GPx) and GSH reductase (GR). GPx neutralizes peroxides by oxidizing GSH into GSH-disulfide (GSSG). In turn, GR reduces GSSG back to GSH. Thus, GPx and GR activities and the GPx/GR-ratio inform about the homeostasis of this system. Two out of three postmortem studies have found lower brain GPx in SZ patients vs. controls[20-22]. Meta-analyses suggest that SZ patients tend to display also lower blood GPx than controls[9]. The decrease in peripheral GPx activity seems, however, mostly found in chronic patients[23]. Among EP patients, those with worse psychosocial outcomes after a 3-year clinical follow-up displayed significantly higher GPx activity at baseline than those with better outcome[24]. By contrast to GPx, there is no evidence of consistent alterations of GR in brain[20] and blood[9].

A possible reason for the discrepancies among studies is the influence of confounding effects of aging[25-27], sex[28] and possibly medication[29] (see Supplementary material in Perkins, Jeffries and Do[8]). For instance, evidence from human plasma [25,30] suggests the GSH-system is maintained until ~45 years of age following which it declines[25]. Similarly, plasma GSH-redox samples showed differences in its expression between males and females [25], while brain GPx measures were higher in females than males, in both animal and human studies[31-33]. This highlights the importance of accounting for the confounding effects of these demographic variables on the GSH-redox measures in relation to disease.

It has been hypothesized that a GSH deficit could participate to the brain white matter (WM) abnormalities in SZ[34,35], consequential to the oligodendrocytes susceptibility to OxS[36], due to their elevated metabolic activity and high iron content for the production and maintenance of the myelin sheaths[37,38]. The GSH redox cycle is involved in the integrity of WM, from the survival, proliferation and differentiation of the oligodendrocyte precursor cells[35,39] (OPC), to the protection of oligodendrocytes against OxS thanks to high GPx expression[40,41]. The dysregulation of the GSH system will also alter axons' energy metabolism[42] and mitochondrial activity[43]. Furthermore, this dysregulation can lead to subclinical activation of microglia[44], which may in turn affect WM, due to its role in the WM myelin remodeling via OPC recruitment and phagocytosis of myelin debris, de-myelination and

remyelination[45]. *Post-mortem* studies on SZ patients have described diminished oligodendrocyte densities in
cortical layer III and subcortical areas, presence of swollen or dystrophic oligodendroglia[46–48], adjacent microglia[49],
and decompacting and splitting of the myelin sheath with inclusions of vacuoles between myelin layers[46–48].
Abnormal WM integrity in EP is also widely reported using *in-vivo* diffusion magnetic resonance imaging (dMRI).
DMRI leverages the random motion of water molecules to infer the microstructural properties of the underlying
biological tissue[50]. Most studies investigating schizophrenia show widespread increased mean diffusivity (MD)
and/or reduced fractional anisotropy (FA)[51–53] with medium effect sizes[53] (*Cohen's d*=0.42), consistent with
anomalies described in the *post-mortem* studies. However, the evidence of a link between WM anomalies and the
GSH system in subjects with schizophrenia remains sparse. GSH levels in frontal brain regions have been found to
correlate positively with generalized FA (gFA) in the cingulum of both EP patients and controls[35], while it was
shown in earlier work that the precursor of GSH and antioxidant, N-acetylcysteine (NAC), improves the integrity of
the fornix (i.e., increases gFA)[54] and increases brain GSH[55] in EP patients.
Here, we aim to assess in patients with a diagnosis of schizophrenia whether the activity of GPx, GR, and the
GPx/GR ratio measured in blood cells (which inform about the systemic homeostasis of the GSH redox cycle) are
associated with the WM microstructure estimated using dMRI. For this purpose, we utilized advanced dMRI
methods: Diffusion Kurtosis Imaging[56,57] (DKI), an extension of diffusion tensor imaging (DTI), and the biophysical
model White Matter Tract Integrity-Watson[58,59] (WMTI-W). In addition to classical DTI measures such as MD and
FA, DKI enables the estimation of the mean kurtosis (MK), a measure of diffusion variance within each voxel arising
from heterogeneous sub-domains, such as cellular compartments, which provides complementary information
about tissue heterogeneity. The WMTI-W model allows the estimation of specific microstructural cellular features
such as the axonal density (f) in each voxel, with fewer *ad hoc* simplifying assumptions and fit constraints[60,61], and
increased validity[61] as compared to other biophysical methods such as free-water imaging[62] (FWI) and Neurite
Orientation Dispersion and Density Imaging[60] (NODDI). We focused our analysis on these four metrics (MD, FA,
MK, f) because of their ability to detect abnormal myelination or demyelination[63–66] (↑MD, ↓FA, ↓MK, ↓f), but also
neuroinflammation which has the effect of reducing diffusivities (↓MD, ↓FA) and increasing kurtosis and apparent
axonal water fraction (↑MK, ↑f) due to higher cellular crowding associated with microgliosis and
astrocytosis[63,64,67,68].
In our previous work on this same cohort and focused on the WM anomalies in EP and SZ vs healthy controls
(HC)[69], we showed that WM MD was higher, while MK and f were lower in EP and SZ than HC. The differences were
more widespread in EP than SZ, and the regional alterations found in our cohort matched the DTI patterns found in
ENIGMA-schizophrenia meta-analysis[53]. Here we hypothesize that alterations in the homeostasis of the systemic
GSH redox cycle may be associated with pathological mechanisms in the brain (i.e., redox dysregulation and
microglia dysfunction) that affect WM. Therefore, we expect that peripheral markers related to the GSH redox cycle
may correlate with some of the WM microstructure metrics, sensitive to neuroinflammation and myelination, as
previous treatment studies targeting the GSH redox system via NAC have shown an increase in brain GSH[55] and
improvement of gFA in the fornix[54].
Furthermore, we expected individuals with high GPx/GR-ratio to have a more oxidized redox state of the
GSH/GSSG couple than those with a low GPx/GR-ratio. Elevated GPx/GR-ratio and/or GPx activity in blood cells
may reflect a condition of systemic OxS, while low GPx/GR-ratio and/or high GR activity may indicate systemic
reductive stress. In fact, PT who benefited from a NAC treatment were mostly those with high blood GPx activity[54].
On the other hand, reductive stress can disturb redox-sensitive biological processes and paradoxically also lead to
increased mitochondrial reactive oxygen species (ROS) production, thus overwhelming the ROS neutralization
capacity and causing mitochondrial dysfunction and oxidative damage[70]. For this reason, we grouped our
participants into high and low GPx/GR-ratio, further testing if could find differences in brain microstructure due to
the different independent expression of oxidative/reductive states in patients. For example, a relatively similar
approach was used to assess changes in low- and high-GPx baseline[55].
Finally, due to the known effect of age[26,27] and sex[31,33] on the expressions of the GSH redox cycle markers, we
explored the role that these confounding variables could have on the link between our peripheral GSH-redox
measurements and WM microstructure.

Methods

Participants

Data were collected from 168 individuals (**Table 1**) divided into two groups: 86 healthy controls (HC) and 82
patients (PT) with a diagnosis from the schizophrenia spectrum (**Supplementary Table S1**). Data were collected
from 168 individuals (Table 1) divided into two groups: 86 healthy controls (HC) and 82 patients (PT) with a
diagnosis of schizophrenia, schizoaffective or schizophreniform disorder as defined by the DSM-IV (Supplementary

Table S1). Patients were recruited from the Lausanne University Hospital. PT with psychosis related to intoxication
or organic brain disease, IQ<70, reporting alcoholism, drug abuse, major somatic disease, documented anamnestic
or current organic brain damage were excluded. HC were recruited from the same sociodemographic area as the
patients. HC were excluded if they had a first-degree family member who suffered from psychosis or prodromal
symptoms, or if they reported current or past antipsychotic treatments. Symptoms in PT were assessed via the
Positive and Negative Syndrome Scale[72] (PANSS), and global functioning was estimated for the whole sample via the
Global Assessment of Function[73] scale (GAF). The study was approved by the local Ethics Committee of the Canton
of Vaud (Switzerland) under authorization numbers CER-VD 382/11 and 2018-01731.
145
MRI acquisition

MRI scanning sessions were performed on two different 3-Tesla systems (Magnetom TrioTim and PRISMA, Siemens
Healthineers, Erlangen, Germany), each equipped with a 32-channel head coil. A 1-mm isotropic T1-weighted
image was acquired for anatomical reference. Whole-brain diffusion-weighted images (DWI) were acquired using
diffusion spectrum imaging (DSI) scheme across 15 b-values, ranging from 0 to 8000 s/mm², spatial resolution of
2.2 x 2.2 x 3 mm³ - See Supplementary Material for further acquisition details.

Image preprocessing

The MPRAGE image was bias field corrected[74] and skull-stripped via nonlinear registration to the MNI-152
template[75] using Advanced Normalization Tools[76] (ANTs). The diffusion preprocessing pipeline included MP-PCA
denoising, Gibbs ringing-, EPI-, eddy current and motion corrections, following most recent guidelines[77] - see
Supplementary Material for preprocessing details.
157
Microstructure estimation

For DKI and WMTI-W estimation, the diffusion dataset was truncated[56] at b≤2500 s/mm² (refer to Supplementary
Methods for details). DKI was fit voxel-wise in the entire brain[78] using a weighted linear-least squares algorithm in
Matlab[78], from which seven scalar maps were derived - four from DTI: RD, MD, AD and FA, and three from DKI:
radial, mean, axial kurtosis (RK, MK, AK). However, only three parameter maps were included in the statistical
analysis: MD, FA, and MK. WMTI-W parameters were estimated voxel-wise from the seven DKI scalars, using an in-
house Python script, yielding five parameter maps: axonal density f, intra-axonal diffusivity D_a, extra-axonal parallel
and perpendicular diffusivities $D_{e,//}$, $D_{e,\perp}$ and axon orientation alignment c_2. However, only axonal density f was
included in the statistical analysis. We focused our analysis on these four metrics (MD, FA, MK, f) because of their
ability at detecting abnormal myelination, demyelination[63–66] (↑MD, ↓FA, ↓MK, ↓f), or neuroinflammation[63,64,67,68]
(↑MD, ↓MK, ↑f).
169
Blood analyses

GR and GPx activity were assessed in hemolyzed blood cells incubated in phosphate buffer solution (100mM, pH
7.5) containing EDTA (0.6mM), and non-limiting levels of either oxidized glutathione (GSSG, 2.5mM) and NADPH
(0.25mM) (for GR), or GSH (2.5mM), NADPH (0.25mM), GR (0.84U/ml; Fluka) and tert-butyl hydroperoxide (TBHP,
0.8mM, Fluka) (for GPx). We expressed GPx and GR activities in nmoles NADPH used/min/g hemoglobin. These
enzymatic activities were measured with two different plate readers. Batch effects between plate readers were
corrected via Combat for biological data[79] (see additional details on the blood analyses and harmonization
procedure in the Supplementary Methods).

Statistical analysis

Blood markers analysis

Statistical analyses were run in R[80], group comparisons were computed via Welch's t-test. Robust linear
regression[81] was used for all the regression and contrast analyses, always including a correction by sex and
quadratic age (see Age Correction section in Supplementary Methods for additional details).

Association between blood markers and WM microstructure

Participants with a delay between MRI scan and blood samples larger than 60 days were excluded whenever an
association between blood biomarkers and WM microstructure metrics was tested (86% of the original cohort,
N_{HC}=80, N_{PT}=65, delay$_{HC}$=10.0±11.7, delay$_{PT}$=17.4±16.0, p=0.0012). All analyses included a correction for quadratic
age, sex, and delay. Associations were tested at voxel level using FSL's Tract-Based Spatial Statistics[82] (TBSS). First,
individual FA maps were used to build a study-specific FA template using ANTs[76] and the estimated warps were
used to spatially normalize each individual FA, MD, MK and f map. Before any statistical analysis, all the

microstructure parameter skeletons were harmonized for scanner type at voxel level in an unbiased way (mean
normalized towards the center of both sites, without reference batch) via ComBat harmonization[83]. ComBat was
previously proven efficient at correcting scanner effects in the ENIGMA-consortium[84], in the current cohort[69,85],
and validated in travelling participants[86]. After permutation testing (FSL randomise[87], 5000 permutations), the
resulting statistical maps were FDR and Threshold-Free Cluster Enhancement (TFCE) corrected.

Low and High GPx/GR ratio analysis

To study if there could be differences between participants showing different levels of GPx and GR activity, we
repeated the analysis described above after re-classifying the participants into two groups according to their
GPx/GR-ratio. Low-ratio and high-ratio were defined as having a GPx/GR-ratio respectively lower and higher than
the median GPx/GR ratio of the HC group (**Fig.1A,** Median$_{HC}$=6.64).

Results

Demographics

Summary demographics of the cohort can be found in **Table 1**. PT (29±9 y/o) and HC (28±8 y/o) did not differ in
age (p=0.21). Differences were found between PT and HC in functional levels as measured by the GAF scale
(p<0.0001) and in the delay between MRI acquisition and blood collection (p<0.0001), leading to the inclusion of
this variable as covariate.

GSH-redox cycle system

Overall, GPx (p=0.69) and GR (p=0.24) activities or the GPx/GR-ratio (p=0.32) did not differ between PT and HC
groups. When pooling together HC and PT, female participants showed higher GPx activity than males (p=0.00071).
GPx and GR activities correlated significantly for the whole cohort (r=0.38, p<0.0001, **Fig. 1A**), but also for PT
(r=0.38, p=0.00038) and HC (r=0.40, p=0.00013) when considered independently. The slope contrast between PT
and HC did not show any significant difference (p=0.80, **Fig. 1B**). GPx and GR activities correlated also in males and
females separately (respectively, r=0.33, p=0.00019 and r=0.46, p=0.00066) with no significant sex difference for
the slopes either (p=0.19, **Fig. 1C**). Age was only found significantly associated with a decrease in GPx activity
when pooling HC and PT together (**Fig. 1D**, p=0.026). No significant association was found with medication.

217
218
Associations between GSH-redox cycle and WM microstructure

TBSS analysis showed significant associations only between GR and MK in HC. No other association for PT or HC
was found between GPx, GR or GPx/GR-ratio with either MD, FA, MK or f. In HC, MK was significantly and
negatively associated with GR in multiple WM clusters (**Fig. 2A**, p=0.00018). Furthermore, the slope (GR–MK) in
HC differed significantly from the regression slope of PT (**Fig. 2B**, p<0.0001). The significant contrast was localized
bilaterally in the anterior and superior corona radiata (CR), genu and body of the corpus callosum (CC).

225
226

Associations between GSH-redox cycle and dMRI WM microstructure in the low and high GPx/GR-ratio
groups

We then assessed how low and high GPx/GR-ratio reflected at the WM microstructure level. First, we established
how the low- vs high-ratio is driven by both GPx and GR levels. Considering both PT and HC together, participants
with low ratio (p<0.0001) had significantly lower GPx (μ$_{GPx}$=13.09) and higher GR (μ$_{GR}$=2.61) as compared to
subjects with high ratio (μ$_{GPx}$=19.86, μ$_{GR}$=2.18). GPx and GR significantly correlated within both low- (r=0.75,
p<0.0001) and high-ratio (r=0.67, p<0.0001) groups.

TBSS voxel-wise analysis of the 3-way interaction model of GPx or GR interacting with low/high-ratio, and clinical
status, showed widespread significant differences in the slopes of MK vs GR between low ratio HC and PT (**Fig. 2C**,
p=0.00031) but not for any other comparison, indicating the low-ratio group drives the difference between HC and
PT found in the previous section. Identified areas for the GR-MK association were the bilateral anterior and
superior CR, genu, splenium and body of the CC, right posterior limb (PLIC) and right retrolenticular part (RLIC) of
the internal capsule. Notably, many voxels of the peripheral WM were also significant.
240

Discussion

In this work, we quantified peripheral biomarkers of the GSH redox cycle (GPx, GR activities and their ratio) in
patients with schizophrenia and control subjects, and we explored the relationships of these redox markers with
the WM microstructure estimated with advanced dMRI methods. We did not find significant differences in GPx, GR
or GPx/GR-ratio between groups. However, female participants showed higher GPx activity than males,
independently of their clinical status. GPx was also the only biomarker whose activity decreased with age. Finally,
GR activity was negatively associated with MK in HC, but not in PT, mostly driven by the subgroup of individuals
with a low GPx/GR-ratio where the differences between HC and PT were enhanced and more widespread across the
WM.
251
252 *Peripheral GSH redox cycle*
253
Many studies have investigated blood GPx and GR activities in cohorts of patients suffering from
schizophrenia[9,22,23,88], sometimes with mixed results. However, meta-analyses[9,23] show overall significantly lower
GPx, but not GR, in PT as compared to HC. To our knowledge, the GPx/GR-ratio has not yet been examined. The
analysis of Flatow et al.[23] indicates that a decrease in GPx activity was prevalent in patients with chronic SZ or in PT
with acute relapse but not with first psychosis episode. In our cohort, which includes PT with early psychosis and
chronic SZ, we did not find any difference between PT and HC regarding GPx, GR and their ratio, even after
correction for age and sex. However, we observed higher GPx activity in females than males and decreased GPx
activity with aging, independently of the clinical status. Thus, some of the discrepancies among studies on PT with
schizophrenia could be explained not only by the stage of the disease, but also by effects on the peripheral markers
of aging[25-27], sex[28] and medication[29] (see Supplementary material in Perkins, Jeffries and Do[8]). Other sources of
variability include methodological differences in sample collection, processing, storage, and quantification.
However, our findings of sex and age effects on blood GPx activity, regardless of the clinical status, corroborate
results from numerous studies[25-28,89]. Higher levels of GPx, but not GR, have been also widely reported in the brain
of females as compared to males in both animal and human studies[31-33]. A higher GPx activity in females is
consistent with more efficient antioxidant systems and less basal inflammation in females than in males[31]. Our
observation of a diminished GPx activity with age is also in line with the literature[30] and with the notion that the
antioxidant defenses weaken over the years, contributing to the accumulation of OxS and its harmful effects[27]. In
our work, we found that GPx and GR activities correlated positively within both PT and HC and within both males
and females, suggesting a generally quite well-coordinated GSH redox cycle. In contrast, the activity of both
enzymes correlated in female adolescents only from the general population[28], but not in EP patients who had been
exposed to childhood trauma[90]. This suggests that the relationship between GPx and GR activities may differ in a
sex-dependent manner during adolescence but also among subgroups of individuals according to environmental
and other yet unidentified factors.
277
278 *Associations between peripheral GSH redox cycle and WM microstructure*
279
Due to the diversity in the GSH redox cycle status across individuals and the complex effects of sex and age, it was
therefore essential to tackle the relationships between the peripheral redox markers and WM microstructure by
carefully considering age, sex and their interactions, and by investigating the links between the GSH redox cycle and
WM separately in subgroups of individuals characterized by different peripheral redox profiles (oxidative vs
reductive stress).
The strongest differences between PT and HC were found in the association of GR with the WM microstructure (**Fig.
2B, C**), particularly with MK. MK is considered a measure of tissue complexity[56,57], which has demonstrated
sensitivity at detecting abnormal myelination[63-66], neurodegeneration and neuroinflammation[67]. Our previous work
on the same data focusing on JHU region-of-interest (ROI) analysis demonstrated that MK was significantly lower in
EP and chronic SZ as compared to age-range matched controls[69]. Our current analysis voxel-wise on the skeleton
revealed that lower MK was associated with higher blood GR activity in HC, but not in PT. This suggests that high GR
activity was linked with changes in myelin and tissue heterogeneity in HC. As high GR activity may be a sign of
reductive stress, we looked at the relationship between GR and MK in individuals with low GPx/GR-ratio, which
proved to be much stronger in this sub-group. This confirmed that the difference in the GR-MK association between
PT and HC were indeed mostly driven by individuals displaying a low GPx/GR-ratio. This suggests that reductive
stress in blood is linked to a low MK in WM of HC, while this does not appear to be the sole modulator of MK in PT.
Here, the lack of a direct association between MK and GR in PT could suggest there are multiple mechanisms
affecting WM integrity in PT, and thus a less direct relationship than in HC.

Prior research has shown that NAC treatment can improve brain GSH levels after six months[55] and WM integrity as
measured by gFA in PT[54]. Notably, improvements in cognitive abilities and in symptoms[55], particularly in individuals
with high GPx levels, have also been reported, highlighting the interplay between blood markers, WM integrity and
cognitive function. Here, however, we found no association between GPx or high-ratio GPx with WM microstructure
in PT, contrary to our expectation, further substantiating the possibility that multiple mechanisms are influencing
the WM integrity in PT.
Interestingly, the spatial localization of the strongest GR-MK significant contrasts between HC and PT (**Fig. 2D**)
coincides with the FA WM ROIs (anterior and superior CR, genu and body of the CC) showing the strongest effect
size between HC and PT found in the large meta-analysis of the ENIGMA study group[53] and similarly reported in our
previous study[69].
Future research on the WM microstructure alterations in SZ should explore their relationship with brain
metabolism more directly. One potential approach is to examine the direct association between brain GSH-redox
levels, measured through MR spectroscopy, and WM microstructure. Furthermore, exploring the involvement of
other brain metabolites could also provide new insights into WM alterations.
312
313 *Limitations*
314
Our study has a few limitations that need to be considered. First, we used harmonization procedures to remove
both the effects of MRI scanner and of plate readers used to quantify the redox markers. In addition, the delay
between MRI acquisition and blood collection could be another source of bias[8] despite being capped and controlled
during the statistical analyses. Second, the heterogeneity among the PT cohort (that includes early psychosis PT
and subjects with chronic SZ) may significantly reduce the statistical power due to potential conflicting trends that
may arise at WM microstructure or GSH-system levels across the different stages and types of psychosis. Third, we
did not apply an additional correction across all modalities and contrasts for the cluster findings (e.g., a second FDR
pass). This decision stems from the large number of voxels resulting from by pooling output images from multiple
TBSS runs, and the inability of a second correction to account for correlations within the blood and microstructure
measures. No finding will survive such conservative correction. Nevertheless, our clusters results, already corrected
with the classical correction (TFCE + FDR) found in TBSS, are large and spatially consistent, suggesting they are
unlikely to be false positives. Lastly, GPx and GR activities and their ratio in blood cells inform us about the systemic
redox homeostasis which does not necessarily reflect the conditions found in the brain. However, several studies
have found associations of peripheral markers of the GSH-redox cycle with brain GSH levels[91], brain atrophy and
enlargement of the lateral ventricles[92], or EEG sensory evoked responses[93].
330
331 *Conclusions*
332
333 Altogether, our association analyses indicate that there is no direct correlation between the peripheral GSH-redox
334 cycle and WM anomalies detected in PT, although a link between reductive stress and WM microstructure was
335 found in HC. Our results do not therefore exclude the involvement of the GSH redox cycle during the
336 development/maturation of WM. The dysregulation of this system during brain development could still contribute
337 to WM anomalies in psychosis and schizophrenia.
338
339
340 **Acknowledgments**
341

This work was supported by the Swiss National Science Foundation (PCEFP2_194260, to I.J.; 320030_197787 to PH
and YA), the National Center of Competence in Research (NCCR) "SYNAPSY - The Synaptic Bases of Mental
Diseases" from the Swiss National Science Foundation (n° 51NF40 – 185897 to KQD & PC) and the Foundation
Alamaya. Dr. Alameda is supported by Carigest fellowship and by Frutiger Adrian et Simone fellowship. Dr. Dwir
and P. Klauser are supported by Frutiger Adrian & Simone fellowship. The authors have nothing to disclose and
there are no conflicts of interest. We are grateful to Gloria Reuteler, Adeline Cottier and Morgane Baumgartner for
expert technical assistance. Dr Luis Alameda thanks the Foundation Adrian and Simone Frutiger and Carigest SA
Foundation for their support

349
350
351 **Competing Interests**
352
353 The authors have no competing interests or other interests that might be perceived to influence the results and/or
353 discussion reported in this paper.
354

Data Availability

357 Data will not be publicly available due to absence of consent from the participants. The code is available here:
358 github.com/tmspvn/python-WMTI-watson
359

360
Author Contributions

362 The authors confirm contribution to the paper as follows: study conception and
363 design: T.P., P.S., I.J., P.K., D.D.; analysis: T.P.;
364 interpretation of results: T.P., P.S., I.J., P.K., D.D., R.J., Z.S.; draft manuscript
365 preparation: T.P., P.S, I.J.; MR data collection: M.C.; manuscript revision and advisory contributions: L.A., K.D., P.C.,
366 and P.H.
367

References

1.   Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B, et al. The size and burden of mental

disorders and other disorders of the brain in Europe 2010. *Eur Neuropsychopharmacol J Eur Coll*

Neuropsychopharmacol. 2011;21(9):655-679. doi:10.1016/j.euroneuro.2011.07.018

2.   McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia—An Overview. *JAMA Psychiatry.*

2020;77(2):201-210. doi:10.1001/jamapsychiatry.2019.3360

3.   Dietz AG, Goldman SA, Nedergaard M. Glial cells in schizophrenia: a unified hypothesis. *Lancet Psychiatry.*

2020;7(3):272-281. doi:10.1016/S2215-0366(19)30302-5

4.   Nakazawa K, Sapkota K. The origin of NMDA receptor hypofunction in schizophrenia. *Pharmacol Ther.*

2020;205:107426. doi:10.1016/j.pharmthera.2019.107426

5.   Ni P, Chung S. Mitochondrial Dysfunction in Schizophrenia. *BioEssays News Rev Mol Cell Dev Biol.*

2020;42(6):e1900202. doi:10.1002/bies.201900202

6.   Murphy CE, Walker AK, Weickert CS. Neuroinflammation in schizophrenia: the role of nuclear factor kappa

B. *Transl Psychiatry.* 2021;11(1):528. doi:10.1038/s41398-021-01607-0

7.   Howes OD, Onwordi EC. The synaptic hypothesis of schizophrenia version III: a master mechanism. *Mol*

Psychiatry. 2023;28(5):1843-1856. doi:10.1038/s41380-023-02043-w

8.   Perkins DO, Jeffries CD, Do KQ. Potential Roles of Redox Dysregulation in the Development of

Schizophrenia. *Biol Psychiatry.* 2020;88(4):326-336. doi:10.1016/j.biopsych.2020.03.016

9.   Tsugawa S, Noda Y, Tarumi R, Mimura Y, Yoshida K, Iwata Y, et al. Glutathione levels and activities of

glutathione metabolism enzymes in patients with schizophrenia: A systematic review and meta-analysis. *J*

Psychopharmacol (Oxf). 2019;33(10):1199-1214. doi:10.1177/0269881119845820

10.   Rambaud V, Marzo A, Chaumette B. Oxidative Stress and Emergence of Psychosis. *Antioxid Basel Switz.*
2022;11(10):1870. doi:10.3390/antiox11101870

11.   Jorgensen A, Baago IB, Rygner Z, Jorgensen MB, Andersen PK, Kessing LV, et al. Association of Oxidative
Stress-Induced Nucleic Acid Damage With Psychiatric Disorders in Adults: A Systematic Review and Meta-analysis.
JAMA Psychiatry. 2022;79(9):920-931. doi:10.1001/jamapsychiatry.2022.2066

12.   Kim SY, Cohen BM, Chen X, Lukas SE, Shinn AK, Yuksel AC, et al. Redox Dysregulation in Schizophrenia
Revealed by in vivo NAD+/NADH Measurement. *Schizophr Bull.* 2017;43(1):197-204. doi:10.1093/schbul/sbw129

13.   Das TK, Javadzadeh A, Dey A, Sabesan P, Théberge J, Radua J, et al. Antioxidant defense in schizophrenia and
bipolar disorder: A meta-analysis of MRS studies of anterior cingulate glutathione. *Prog Neuropsychopharmacol*
Biol Psychiatry. 2019;91:94-102. doi:10.1016/j.pnpbp.2018.08.006

14.   Ma J, Li DM, Zhang R, Yang XD, Gao CG, Lu SM, et al. Genetic analysis of glutamate cysteine ligase modifier
(GCLM) gene and schizophrenia in Han Chinese. *Schizophr Res.* 2010;119(1-3):273-274.
doi:10.1016/j.schres.2009.12.017

15.   Tosic M, Ott J, Barral S, Bovet P, Deppen P, Gheorghita F, et al. Schizophrenia and Oxidative Stress: Glutamate
Cysteine Ligase Modifier as a Susceptibility Gene. *Am J Hum Genet.* 2006;79(3):586-592. doi:10.1086/507566

16.   Rodríguez-Santiago B, Brunet A, Sobrino B, Serra-Juhé C, Flores R, Armengol L, et al. Association of
common copy number variants at the glutathione S-transferase genes and rare novel genomic changes with
schizophrenia. *Mol Psychiatry.* 2010;15(10):1023-1033. doi:10.1038/mp.2009.53

17.   Gravina P, Spoletini I, Masini S, Valentini A, Vanni D, Paladini E, et al. Genetic polymorphisms of glutathione
S-transferases GSTM1, GSTT1, GSTP1 and GSTA1 as risk factors for schizophrenia. *Psychiatry Res.*
2011;187(3):454-456. doi:10.1016/j.psychres.2010.10.008

18.   Yan C, Duan L, Fu C, Tian C, Zhang B, Shao X, et al. Association Between Glutathione S-Transferase (GST)
Polymorphisms and Schizophrenia in a Chinese Han Population. *Neuropsychiatr Dis Treat.* 2020;16(null):479-487.
doi:10.2147/NDT.S235043

19.   Gysin R, Kraftsik R, Sandell J, Bovet P, Chappuis C, Conus P, et al. Impaired glutathione synthesis in
schizophrenia: Convergent genetic and functional evidence. *Proc Natl Acad Sci.* 2007;104(42):16621-16626.
doi:10.1073/pnas.0706778104

20.   Yao JK, Leonard S, Reddy R. Altered Glutathione Redox State in Schizophrenia. *Dis Markers.*
NaN/NaN/NaN;22(1-2):83-93. doi:10.1155/2006/248387

21. Gawryluk JW, Wang JF, Andreazza AC, Shao L, Young LT. Decreased levels of glutathione, the major brain
antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. *Int J*
Neuropsychopharmacol. 2011;14(1):123-130. doi:10.1017/S1461145710000805

22. Zhang Y, Catts VS, Shannon Weickert C. Lower antioxidant capacity in the prefrontal cortex of individuals
with schizophrenia. *Aust N Z J Psychiatry.* 2018;52(7):690-698. doi:10.1177/0004867417728805

23. Flatow J, Buckley P, Miller BJ. Meta-Analysis of Oxidative Stress in Schizophrenia. *Biol Psychiatry.*
2013;74(6):400-409. doi:10.1016/j.biopsych.2013.03.018

24. Fournier M, Scolamiero M, Gholam-Rezaee MM, Cleusix M, Jenni R, Ferrari C, et al. Topology predicts long-
term functional outcome in early psychosis. *Mol Psychiatry.* 2021;26(9):5335-5346. doi:10.1038/s41380-020-
0826-1

25. Jones DP, Mody VC, Carlson JL, Lynn MJ, Sternberg P. Redox analysis of human plasma allows separation of
pro-oxidant events of aging from decline in antioxidant defenses. *Free Radic Biol Med.* 2002;33(9):1290-1300.
doi:10.1016/S0891-5849(02)01040-7

26. Martínez de Toda I, Vida C, Sanz San Miguel L, De la Fuente M. Function, Oxidative, and Inflammatory Stress
Parameters in Immune Cells as Predictive Markers of Lifespan throughout Aging. *Oxid Med Cell Longev.*
2019;2019:4574276. doi:10.1155/2019/4574276

27. Stadtman ER. Importance of individuality in oxidative stress and aging. *Free Radic Biol Med.*
2002;33(5):597-604. doi:10.1016/s0891-5849(02)00904-8

28. Schilliger Z, Alemán-Gómez Y, Magnus Smith M, Celen Z, Meuleman B, Binz PA, et al. Sex-specific
interactions between stress axis and redox balance are associated with internalizing symptoms and brain white
matter microstructure in adolescents. *Transl Psychiatry.* 2024;14(1):1-11. doi:10.1038/s41398-023-02728-4

29. Raffa M, Mechri A, Othman LB, Fendri C, Gaha L, Kerkeni A. Decreased glutathione levels and antioxidant
enzyme activities in untreated and treated schizophrenic patients. *Prog Neuropsychopharmacol Biol Psychiatry.*
2009;33(7):1178-1183. doi:10.1016/j.pnpbp.2009.06.018

30. Martínez De Toda I, Vida C, Garrido A, De La Fuente M. Redox Parameters as Markers of the Rate of Aging
and Predictors of Life Span. *J Gerontol Ser A.* February 2019. doi:10.1093/gerona/glz033

31. Martínez de Toda I, González-Sánchez M, Díaz-Del Cerro E, Valera G, Carracedo J, Guerra-Pérez N. Sex
differences in markers of oxidation and inflammation. Implications for ageing. *Mech Ageing Dev.* 2023;211:111797.
doi:10.1016/j.mad.2023.111797

32.   Dukhande VV, Isaac AO, Chatterji T, Lai JCK. Reduced glutathione regenerating enzymes undergo

developmental decline and sexual dimorphism in the rat cerebral cortex. *Brain Res*. 2009;1286:19-24.

doi:10.1016/j.brainres.2009.05.029

33.   Ruszkiewicz JA, Miranda-Vizuete A, Tinkov AA, Skalnaya MG, Skalny AV, Tsatsakis A, et al. Sex-Specific

Differences in Redox Homeostasis in Brain Norm and Disease. *J Mol Neurosci*. 2019;67(2):312-342.

doi:10.1007/s12031-018-1241-9

34.   Monin A, Fournier M, Baumann PS, Cuénod M, Do KQ. Role of Redox Dysregulation in White Matter

Anomalies Associated with Schizophrenia. In: *Handbook of Behavioral Neuroscience*. Vol 23. Elsevier; 2016:481-

500. doi:10.1016/B978-0-12-800981-9.00028-6

35.   Monin A, Baumann PS, Griffa A, Xin L, Mekle R, Fournier M, et al. Glutathione deficit impairs myelin

maturation: relevance for white matter integrity in schizophrenia patients. *Mol Psychiatry*. 2015;20(7):827-838.

doi:10.1038/mp.2014.88

36.   Juurlink BH, Thorburne SK, Hertz L. Peroxide-scavenging deficit underlies oligodendrocyte susceptibility to

oxidative stress. *Glia*. 1998;22(4):371-378. doi:10.1002/(sici)1098-1136(199804)22:4<371::aid-glia6>3.0.co;2-6

37.   Bradl M, Lassmann H. Oligodendrocytes: biology and pathology. *Acta Neuropathol (Berl)*. 2010;119(1):37-

53. doi:10.1007/s00401-009-0601-5

38.   Thorburne SK, Juurlink BH. Low glutathione and high iron govern the susceptibility of oligodendroglial

precursors to oxidative stress. *J Neurochem*. 1996;67(3):1014-1022. doi:10.1046/j.1471-4159.1996.67031014.x

39.   Back SA, Gan X, Li Y, Rosenberg PA, Volpe JJ. Maturation-Dependent Vulnerability of Oligodendrocytes to

Oxidative Stress-Induced Death Caused by Glutathione Depletion. *J Neurosci*. 1998;18(16):6241-6253.

doi:10.1523/JNEUROSCI.18-16-06241.1998

40.   Ravera S, Bartolucci M, Cuccarolo P, Litamè E, Illarcio M, Calzia D, et al. Oxidative stress in myelin sheath:

The other face of the extramitochondrial oxidative phosphorylation ability. *Free Radic Res*. 2015;49(9):1156-1164.

doi:10.3109/10715762.2015.1050962

41.   Baud O, Greene AE, Li J, Wang H, Volpe JJ, Rosenberg PA. Glutathione peroxidase-catalase cooperativity is

required for resistance to hydrogen peroxide by mature rat oligodendrocytes. *J Neurosci Off J Soc Neurosci*.

2004;24(7):1531-1540. doi:10.1523/JNEUROSCI.3989-03.2004

42.   Nave KA, Asadollahi E, Sasmita A. Expanding the function of oligodendrocytes to brain energy metabolism.

Curr Opin Neurobiol. 2023;83:102782. doi:10.1016/j.conb.2023.102782

43.   Smith GA, Lin TH, Sheehan AE, Van der Goes van Naters W, Neukomm LJ, Graves HK, et al. Glutathione S-
Transferase Regulates Mitochondrial Populations in Axons through Increased Glutathione Oxidation. *Neuron.*
2019;103(1):52-65.e6. doi:10.1016/j.neuron.2019.04.017

44.   Dwir D, Giangreco B, Xin L, Tenenbaum L, Cabungcal JH, Steullet P, et al. MMP9/RAGE pathway
overactivation mediates redox dysregulation and neuroinflammation, leading to inhibitory/excitatory imbalance: a
reverse translation study in schizophrenia patients. *Mol Psychiatry.* 2020;25(11):2889-2904. doi:10.1038/s41380-
019-0393-5

45.   Lloyd AF, Davies CL, Miron VE. Microglia: origins, homeostasis, and roles in myelin repair. *Curr Opin*
Neurobiol. 2017;47:113-120. doi:10.1016/j.conb.2017.10.001

46.   Uranova NA, Vikhreva OV, Rachmanova VI, Orlovskaya DD. Ultrastructural Alterations of Myelinated Fibers
and Oligodendrocytes in the Prefrontal Cortex in Schizophrenia: A Postmortem Morphometric Study. *Schizophr Res*
Treat. 2011;2011:e325789. doi:10.1155/2011/325789

47.   Uranova NA, Vikhreva OV, Rakhmanova VI, Orlovskaya DD. Ultrastructural pathology of oligodendrocytes
adjacent to microglia in prefrontal white matter in schizophrenia. *Npj Schizophr.* 2018;4(1):1-10.
doi:10.1038/s41537-018-0068-2

48.   Williams M, ed. *The Neuropathology of Schizophrenia.* Cham: Springer International Publishing; 2021.
doi:10.1007/978-3-030-68308-5

49.   Uranova NA, Vikhreva OV, Rakhmanova VI, Orlovskaya DD. Dystrophy of Oligodendrocytes and Adjacent
Microglia in Prefrontal Gray Matter in Schizophrenia. *Front Psychiatry.* 2020;11.
https://www.frontiersin.org/articles/10.3389/fpsyt.2020.00204. Accessed March 10, 2023.

50.   Beaulieu C. The basis of anisotropic water diffusion in the nervous system - a technical review. *NMR*
Biomed. 2002;15(7-8):435-455. doi:10.1002/nbm.782

51.   Cetin-Karayumak S, Di Biase MA, Chunga N, Reid B, Somes N, Lyall AE, et al. White matter abnormalities
across the lifespan of schizophrenia: a harmonized multi-site diffusion MRI study. *Mol Psychiatry.*
2020;25(12):3208-3219. doi:10.1038/s41380-019-0509-y

52.   Barth C, Kelly S, Nerland S, Jahanshad N, Alloza C, Ambrogi S, et al. In vivo white matter microstructure in
adolescents with early-onset psychosis: a multi-site mega-analysis. *Mol Psychiatry.* 2023;28(3):1159-1169.
doi:10.1038/s41380-022-01901-3

53.   Kelly S, Jahanshad N, Zalesky A, Kochunov P, Agartz I, Alloza C, et al. Widespread white matter
microstructural differences in schizophrenia across 4322 individuals: results from the ENIGMA Schizophrenia DTI
Working Group. *Mol Psychiatry.* 2018;23(5):1261-1269. doi:10.1038/mp.2017.170

54.   Klauser P, Xin L, Fournier M, Griffa A, Cleusix M, Jenni R, et al. N-acetylcysteine add-on treatment leads to an

improvement of fornix white matter integrity in early psychosis: a double-blind randomized placebo-controlled

trial. *Transl Psychiatry*. 2018;8(1):1-8. doi:10.1038/s41398-018-0266-8

55.   Conus P, Seidman LJ, Fournier M, Xin L, Cleusix M, Baumann PS, et al. N-acetylcysteine in a Double-Blind

Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis. *Schizophr Bull*.

2018;44(2):317-327. doi:10.1093/schbul/sbx093

56.   Jensen JH, Helpern JA, Ramani A, Lu H, Kaczynski K. Diffusional kurtosis imaging: The quantification of non-

gaussian water diffusion by means of magnetic resonance imaging. *Magn Reson Med*. 2005;53(6):1432-1440.

doi:10.1002/mrm.20508

57.   Jensen JH, Helpern JA. MRI quantification of non-Gaussian water diffusion by kurtosis analysis. *NMR

Biomed*. 2010;23(7):698-710. doi:10.1002/nbm.1518

58.   Jespersen SN, Olesen JL, Hansen B, Shemesh N. Diffusion time dependence of microstructural parameters in

fixed spinal cord. *NeuroImage*. 2018;182:329-342. doi:10.1016/j.neuroimage.2017.08.039

59.   Fieremans E, Jensen JH, Helpern JA. White matter characterization with diffusional kurtosis imaging.

NeuroImage. 2011;58(1):177-188. doi:10.1016/j.neuroimage.2011.06.006

60.   Zhang H, Schneider T, Wheeler-Kingshott CA, Alexander DC. NODDI: practical in vivo neurite orientation

dispersion   and   density   imaging   of   the   human   brain.   *NeuroImage*.   2012;61(4):1000-1016.

doi:10.1016/j.neuroimage.2012.03.072

61.   Novikov DS, Kiselev VG, Jespersen SN. On modeling. *Magn Reson Med*. 2018;79(6):3172-3193.

doi:10.1002/mrm.27101

62.   Pasternak O, Sochen N, Gur Y, Intrator N, Assaf Y. Free water elimination and mapping from diffusion MRI.

Magn Reson Med. 2009;62(3):717-730. doi:10.1002/mrm.22055

63.   Guglielmetti C, Veraart J, Roelant E, Mai Z, Daans J, Van Audekerke J, et al. Diffusion kurtosis imaging probes

cortical alterations and white matter pathology following cuprizone induced demyelination and spontaneous

remyelination. *NeuroImage*. 2016;125:363-377. doi:10.1016/j.neuroimage.2015.10.052

64.   Jelescu IO, Zurek M, Winters KV, Veraart J, Rajaratnam A, Kim NS, et al. In vivo quantification of

demyelination and recovery using compartment-specific diffusion MRI metrics validated by electron microscopy.

NeuroImage. 2016;132:104-114. doi:10.1016/j.neuroimage.2016.02.004

65.   Wang Y, Wang Q, Haldar JP, Yeh FC, Xie M, Sun P, et al. Quantification of increased cellularity during

inflammatory demyelination. *Brain*. 2011;134(12):3590-3601. doi:10.1093/brain/awr307

66.   Falangola MF, Guilfoyle DN, Tabesh A, Hui ES, Nie X, Jensen JH, et al. Histological correlation of diffusional
kurtosis and white matter modeling metrics in cuprizone-induced corpus callosum demyelination. *NMR Biomed*.
2014;27(8):948-957. doi:10.1002/nbm.3140

67.   Jelescu IO, Fieremans E. Chapter 2 - Sensitivity and specificity of diffusion MRI to neuroinflammatory
processes. In: Laule C, Port JD, eds. *Advances in Magnetic Resonance Technology and Applications*. Vol 9. Imaging
Neuroinflammation. Academic Press; 2023:31-50. doi:10.1016/B978-0-323-91771-1.00010-1

68.   Wijtenburg SA, Rowland LM. Chapter 19 - Schizophrenia spectrum disorders. In: Laule C, Port JD, eds.
Advances in Magnetic Resonance Technology and Applications. Vol 9. Imaging Neuroinflammation. Academic Press;
2023:469-487. doi:10.1016/B978-0-323-91771-1.00008-3

69.   Pavan T, Alemán-Gómez Y, Jenni R, Steullet P, Schilliger Z, Dwir D, et al. White Matter Microstructure
Alterations in Early Psychosis and Schizophrenia. April 2024:2024.02.01.24301979.
doi:10.1101/2024.02.01.24301979

70.   Korge P, Calmettes G, Weiss JN. Increased reactive oxygen species production during reductive stress: The
roles of mitochondrial glutathione and thioredoxin reductases. *Biochim Biophys Acta BBA - Bioenerg*.
2015;1847(6):514-525. doi:10.1016/j.bbabio.2015.02.012

71.   Yung AR, Yuen HP, McGorry PD, Phillips LJ, Kelly D, Dell'Olio M, et al. Mapping the onset of psychosis: the
Comprehensive Assessment of At-Risk Mental States. *Aust N Z J Psychiatry*. 2005;39(11-12):964-971.
doi:10.1080/j.1440-1614.2005.01714.x

72.   Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia.
Schizophr Bull. 1987;13(2):261-276. doi:10.1093/schbul/13.2.261

73.   American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders (4th Ed., Text Rev.).*;
2000.

74.   Tustison NJ, Avants BB, Cook PA, Zheng Y, Egan A, Yushkevich PA, et al. N4ITK: improved N3 bias correction.
IEEE Trans Med Imaging. 2010;29(6):1310-1320. doi:10.1109/TMI.2010.2046908

75.   Grabner G, Janke AL, Budge MM, Smith D, Pruessner J, Collins DL. Symmetric Atlasing and Model Based
Segmentation: An Application to the Hippocampus in Older Adults. In: Larsen R, Nielsen M, Sporring J, eds. *Medical
Image Computing and Computer-Assisted Intervention – MICCAI 2006*. Lecture Notes in Computer Science. Berlin,
Heidelberg: Springer; 2006:58-66. doi:10.1007/11866763_8

76.   Avants BB, Epstein CL, Grossman M, Gee JC. Symmetric diffeomorphic image registration with cross-
correlation: evaluating automated labeling of elderly and neurodegenerative brain. *Med Image Anal*.
2008;12(1):26-41. doi:10.1016/j.media.2007.06.004

77.   Ades-Aron B, Veraart J, Kochunov P, McGuire S, Sherman P, Kellner E, et al. Evaluation of the accuracy and

precision of the diffusion parameter EStImation with Gibbs and NoisE removal pipeline. *NeuroImage*.

2018;183:532-543. doi:10.1016/j.neuroimage.2018.07.066

78.   Veraart J, Sijbers J, Sunaert S, Leemans A, Jeurissen B. Weighted linear least squares estimation of diffusion

MRI   parameters: Strengths,   limitations,   and   pitfalls.   *NeuroImage*.   2013;81:335-346.

doi:10.1016/j.neuroimage.2013.05.028

79.   Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes

methods. *Biostat Oxf Engl*. 2007;8(1):118-127. doi:10.1093/biostatistics/kxj037

80.   R Core Team. *R: A Language and Environment for Statistical Computing*. Vienna, Austria: R Foundation for

Statistical Computing; 2023. https://www.R-project.org/.

81.   Maechler M, Rousseeuw P, Croux C, Todorov V, Ruckstuhl A, Salibian-Barrera M, et al. *Robustbase: Basic

Robust Statistics.*; 2023. http://robustbase.r-forge.r-project.org/.

82.   Smith SM, Jenkinson M, Johansen-Berg H, Rueckert D, Nichols TE, Mackay CE, et al. Tract-based spatial

statistics: voxelwise   analysis   of   multi-subject   diffusion   data.   *NeuroImage*.   2006;31(4):1487-1505.

doi:10.1016/j.neuroimage.2006.02.024

83.   Fortin JP, Parker D, Tunç B, Watanabe T, Elliott MA, Ruparel K, et al. Harmonization of multi-site diffusion

tensor imaging data. *NeuroImage*. 2017;161:149-170. doi:10.1016/j.neuroimage.2017.08.047

84.   Radua J, Vieta E, Shinohara R, Kochunov P, Quidé Y, Green MJ, et al. Increased power by harmonizing

structural MRI site differences with the ComBat batch adjustment method in ENIGMA. *NeuroImage*.

2020;218:116956. doi:10.1016/j.neuroimage.2020.116956

85.   Alemán-Gómez Y, Najdenovska E, Roine T, Fartaria MJ, Canales-Rodríguez EJ, Rovó Z, et al. Partial-volume

modeling reveals reduced gray matter in specific thalamic nuclei early in the time course of psychosis and chronic

schizophrenia. *Hum Brain Mapp*. 2020;41(14):4041-4061. doi:10.1002/hbm.25108

86.   Richter S, Winzeck S, Correia MM, Kornaropoulos EN, Manktelow A, Outtrim J, et al. Validation of cross-

sectional and longitudinal ComBat harmonization methods for magnetic resonance imaging data on a travelling

subject cohort. *Neuroimage Rep*. 2022;2(4):100136. doi:10.1016/j.ynirp.2022.100136

87.   Winkler AM, Ridgway GR, Webster MA, Smith SM, Nichols TE. Permutation inference for the general linear

model. *NeuroImage*. 2014;92:381-397. doi:10.1016/j.neuroimage.2014.01.060

88.   Koga M, Serritella AV, Sawa A, Sedlak TW. Implications for reactive oxygen species in schizophrenia

pathogenesis. *Schizophr Res*. 2016;176(1):52-71. doi:10.1016/j.schres.2015.06.022

89.   Abdalla DS, Monteiro HP, Oliveira JA, Bechara EJ. Activities of superoxide dismutase and glutathione

peroxidase   in   schizophrenic   and   manic-depressive   patients.   *Clin   Chem*.   1986;32(5):805-807.

doi:10.1093/clinchem/32.5.805

90.   Alameda L, Fournier M, Khadimallah I, Griffa A, Cleusix M, Jenni R, et al. Redox dysregulation as a link

between childhood trauma and psychopathological and neurocognitive profile in patients with early psychosis.

Proc Natl Acad Sci U S A. 2018;115(49):12495-12500. doi:10.1073/pnas.1812821115

91.   Xin L, Mekle R, Fournier M, Baumann PS, Ferrari C, Alameda L, et al. Genetic Polymorphism Associated

Prefrontal Glutathione and Its Coupling With Brain Glutamate and Peripheral Redox Status in Early Psychosis.

Schizophr Bull. 2016;42(5):1185-1196. doi:10.1093/schbul/sbw038

92.   Buckman TD, Kling AS, Eiduson S, Sutphin MS, Steinberg A. Glutathione peroxidase and CT scan

abnormalities in schizophrenia. *Biol Psychiatry*. 1987;22(11):1349-1356. doi:10.1016/0006-3223(87)90069-2

93.   Geiser E, Retsa C, Knebel JF, Ferrari C, Jenni R, Fournier M, et al. The coupling of low-level auditory

dysfunction   and   oxidative   stress   in   psychosis   patients.   *Schizophr   Res*.   2017;190:52-59.

doi:10.1016/j.schres.2017.02.002

Tables

615 **Tables**

		HC (N=86)		PT (N=82)			
		Mean	Std.	Men	Std.	Stat.	p-value
Age (years)		28.1	8.6	29.8	9.6	W=3130	p=2.1e-01ns
GPx		16.7	6.6	16.3	6.2		
GR		2.5	0.7	2.3	0.7		
GPx/GR-ratio		6.9	2.7	7.4	3.3		
Delay MRI-Biomarker (days)[†]		17.9	31.7	36.7[†]	44.5[†]	W=2249	p=4.4e-05****
Age at Psychosis Onset (years)				23.4	7.7		
Duration of illness (months)				68.7	86.7		
CPZ-equivalent dose (mg/day)				357.1	288.9		
PANSS: total				63.5	14.9		
PANSS: positive symptoms				13.6	4.4		
PANSS: negative symptoms				17.2	5.7		
PANSS: general psychopathology				33.0	8.0		
GAF		84.9	4.1	54.9	11.8	W=6608	p=3.9e-28****
		N	Pct.	N	Pct.		
Scanner	Prisma	68	79.1	60	73.2	χ^2:0.81	p=0.37
	Trio	18	20.9	22	26.8		
Sex	Female	32	37.2	18	22.0	χ^2:4.68	p=0.031*
	Male	54	62.8	64	78.0		
Reader	Infinite	66	76.7	75	91.5	χ^2:6.742	p=0.009*
	SPARK	20	23.3	7	8.5		
GPx/GR-Ratio	High	44	51.2	40	48.8		
	Low	42	48.8	42	51.2		

617 **Table 1** Cohort demographics. P-values refer to Wilcox's tests between patients and healthy control. χ2 test is computed for
618 the scanner, sex, and reader contingency tables. GPx and GR activities are expressed in nmoles NADPH used/min/g hemoglobin.
619 HC: healthy controls, PT: patients, GPx: glutathione peroxidase, GR: glutathione reductase, GAF: Global Assessment of
620 Functioning, PANSS: Positive and Negative Syndrome Scale. †: the delay MRI-biomarker statistics are reported excluding one PT
621 participant with an extreme delay of 271 days.

Figures Captions

Figure 1

Biomarkers of the blood GSH-redox cycle and the effects of sex, age and clinical status. Correlations between GPx and GR activity in the whole cohort, colored by the quartiles of the ratio between GPx and GR (A), clinical status (B), and sex (C). Association between GPx and age (D) for both the entire cohort (shaded gray area) and by clinical status. GPx and GR activities are expressed in nmoles NADPH used/min/g hemoglobin. GPx: GSH peroxidase; GR: GSH reductase; HC: healthy controls; PT: patients; M: males; F: females.

Figure 2

Significant associations between biomarkers of the blood GSH-redox cycle and the dMRI microstructure estimates. (A, B): Brain plots show the significant association clusters between MK and GR activity (p_{fdr}≤0.05). GR was found significantly associated with MK in HC (A), with a slope that differed from the PT slope (B). (C): Brain plots show the significant clusters where the association of MK with GR in individuals with low GPx/GR-ratio yielded a different slope between HC and PT (p_{fdr}≤0.05). The regression plots show the association average values within significant clusters. Clusters were identified in the bilateral anterior and superior corona radiata, as well as in the genu and body of the corpus callosum and sections of the internal capsule. Results are corrected for quadratic age, sex, and delay. GR and $GR_{Low-ratio}$ are centered. Green: WM skeleton; HC: healthy controls; PT: patients; GR: glutathione reductase; MK: mean kurtosis; β_{HC}: slope of HC; β_{PT}: slope of the PT; Low-ratio: participants with GPx/GR-ratio < median ratio of the HC group (6.64).

A) $MK \sim GR$: $\beta_{HC} < 0$

p=0.00018

B) $MK \sim GR$: $\beta_{EP} > \beta_{HC}$

p<0.0001

C) $MK \sim GR_{Low-Ratio}$: $\beta_{EP} > \beta_{HC}$

p=0.00031

L

EP   HC